Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126909
Títol: High MICs for Vancomycin and Daptomycin and Complicated Catheter-Related Bloodstream Infections with Methicillin-Sensitive Staphylococcus aureus
Autor: San Juan, Rafael
Viedma, Esther
Chaves, Fernando
Lalueza, Antonio
Fortún, Jesús
Loza, Elena
Pujol Rojo, Miquel
Ardanuy Tisaire, María Carmen
Morales, Isabel
Cueto, Marina de
Resino Foz, Elena
Morales Cartagena, Alejandra
Rico, Alicia
Romero, María P.
Orellana, María Ángeles
López Medrano, Francisco
Fernández Ruiz, Mario
Aguado, José María
Matèria: Sang
Malalties bacterianes
Factors de risc en les malalties
Efecte dels medicaments sobre els microorganismes
Blood
Bacterial diseases
Risk factors in diseases
Effect of drugs on microorganisms
Data de publicació: juny-2016
Publicat per: Centers for Disease Control and Prevention
Resum: We investigated the prognostic role of high MICs for antistaphylococcal agents in patients with methicillin-sensitive Staphylococcus aureus catheter-related bloodstream infection (MSSA CRBSI). We prospectively reviewed 83 episodes from 5 centers in Spain during April 2011 June 2014 that had optimized clinical management and analyzed the relationship between E-test MICs for vancomycin, daptomycin, oxacillin, and linezolid and development of complicated bacteremia by using multivariate analysis. Complicated MSSA CRBSI occurred in 26 (31.3%) patients; MICs for vancomycin and daptomycin were higher in these patients (optimal cutoff values for predictive accuracy = 1.5 mu g/mL and 0.5 mu g/mL). High MICs for vancomycin (hazard ratio 2.4, 95% CI 1.2-5.5) and daptomycin (hazard ratio 2.4, 95% CI 1.1-5.9) were independent risk factors for development of complicated MSSA CRBSI. Our data suggest that patients with MSSA CRBSI caused by strains that have high MICs for vancomycin or daptomycin are at increased risk for complications.
Nota: Reproducció del document publicat a: https://doi.org/10.3201/eid2206.151709
És part de: Emerging Infectious Diseases, 2016, vol. 22, num. 6, p. 1057-1066
URI: https://hdl.handle.net/2445/126909
Recurs relacionat: https://doi.org/10.3201/eid2206.151709
ISSN: 1080-6040
Apareix en les col·leccions:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Fitxers d'aquest document:
Fitxer Descripció DimensionsFormat 
662472.pdf1.55 MBAdobe PDFMostrar/Obrir


Aquest document té tots els drets reservats